Press ReleasesFollow CatalYm’s journey and learn more about our most recent milestones March 1, 2022 CatalYm Commences Phase 2 Development of GDF-15-Targeting Antibody CTL-002 Following Successful Phase 1 Completion - Read More November 12, 2021 CatalYm Presents Expanded Clinical and New Preclinical Data from GDF-15-targeting Program CTL-002 at SITC Conference - Read More October 11, 2021 CatalYm Presents Updated Tolerability & Preliminary Pharmacodynamics Data from GDF-15 targeting First-in-Human Clinical Trial... - Read More Load MoreLoadingMeet us at the following conferences & events BIO EUROPE SPRING 2022 March 28-31, 2022 Virtual Read More AACR 2022 April 8-13, 2022 New Orleans, Louisiana, USA Read More ASCO 2022 June 3-7, 2022 Chicago, IL, USA Read More BIO 2022 June 13-16, 2022 San Diego, CA, USA Read More ESMO 2022 September 9-13, 2022 Paris, France Read More SITC 2022 November 8-12, 2022 Boston, MA, USA Read More
